HLA B eplet mismatches in the context of delayed graft function and low tacrolimus trough levels are risk factors influencing the generation of de novo donor-specific antibodies and acute rejection in the early stage after kidney transplantation

Transpl Immunol. 2023 Dec:81:101955. doi: 10.1016/j.trim.2023.101955. Epub 2023 Nov 4.

Abstract

Background: De novo donor-specific antibody (dnDSA) generation and acute rejection (AR) are the main factors affecting long-term graft survival. This study aims to investigate human leukocyte antigen (HLA) eplet mismatching (MM), delayed graft function (DGF), and tacrolimus (TAC) trough levels on the occurrence of dnDSA and AR in the early stages after kidney transplantation (KT).

Methods: This retrospective study included 526 cases of deceased donation KT. The effects of DGF, HLA eplet MM, and TAC trough levels on dnDSA and AR occurrence were analyzed with logistic regression analysis.

Results: Multivariate logistic regression analysis showed the independent risk factor of dnDSA generation was HLA B eplet MM (OR: 1.201, 95% CI: 1.007-1.431, P = 0.041). The independent risk factors of AR occurrence include DGF (OR: 4.045, 95% CI: 1.047-15.626, P = 0.043), HLA B eplet MM (OR: 1.090, 95% CI: 1.000-1.187, P = 0.050), and TAC trough levels at 12 months (OR: 0.750, 95% CI: 565-0.997, P = 0.048). HLA B eplet MM combined with DGF and TAC trough levels at 12 months increased the predictive value of dnDSA (AUC 0.735) and AR (AUC 0.730) occurrence. HLA B eplet MM > 9 and TAC trough levels below 5.95 ng/mL at 12 months could increase the risk of early AR occurrence.

Conclusions: HLA B eplet MM, DGF, and TAC trough levels at 12 months after KT could affect the occurrence of dnDSA and AR in the early stage of KT.

Keywords: Acute rejection; Delayed graft function; Eplet; Kidney transplantation; Tacrolimus; dnDSA.

MeSH terms

  • Antibodies
  • Delayed Graft Function
  • Graft Rejection
  • Graft Survival
  • HLA Antigens
  • HLA-B Antigens
  • Histocompatibility Antigens Class II
  • Humans
  • Kidney Transplantation*
  • Retrospective Studies
  • Risk Factors
  • Tacrolimus / therapeutic use

Substances

  • Tacrolimus
  • Antibodies
  • HLA Antigens
  • Histocompatibility Antigens Class II
  • HLA-B Antigens